Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) Return on Capital Employed (2022 - 2025)

Historic Return on Capital Employed for Prime Medicine (PRME) over the last 4 years, with Q3 2025 value amounting to 0.69%.

  • Prime Medicine's Return on Capital Employed rose 1900.0% to 0.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.69%, marking a year-over-year increase of 1900.0%. This contributed to the annual value of 0.97% for FY2024, which is 500.0% down from last year.
  • Latest data reveals that Prime Medicine reported Return on Capital Employed of 0.69% as of Q3 2025, which was up 1900.0% from 0.76% recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Return on Capital Employed registered a high of 0.43% during Q1 2023, and its lowest value of 1.28% during Q4 2023.
  • Moreover, its 4-year median value for Return on Capital Employed was 0.75% (2025), whereas its average is 0.76%.
  • In the last 5 years, Prime Medicine's Return on Capital Employed tumbled by -8300bps in 2023 and then surged by 5500bps in 2024.
  • Quarter analysis of 4 years shows Prime Medicine's Return on Capital Employed stood at 0.45% in 2022, then plummeted by -187bps to 1.28% in 2023, then soared by 43bps to 0.73% in 2024, then grew by 6bps to 0.69% in 2025.
  • Its Return on Capital Employed stands at 0.69% for Q3 2025, versus 0.76% for Q2 2025 and 0.74% for Q1 2025.